INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 ...

Please provide your email address to receive an email when new articles are posted on . Infants diagnosed with atopic dermatitis are more likely to develop asthma, allergic rhinitis and food allergies ...

Please provide your email address to receive an email when new articles are posted on . AD onset in infants was significantly delayed with high vs. low dietary diversity during pregnancy. There was a ...

Learn the red flags that indicate the eczema treatment plan you’re on isn’t working.

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children ...

WESTLAKE VILLAGE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Chronic and highly burdensome, atopic dermatitis affects an estimated 223 million people worldwide, with onset commonly ...

Having infant colic, characterized by unsoothable crying and apparent abdominal discomfort, was associated with an increased risk for atopic conditions and respiratory illnesses throughout childhood ...

The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application for topical roflumilast, 0.05%, for the treatment of mild to moderate atopic dermatitis (AD) in children aged ...